Orchid Pharma Limited has informed the Exchange regarding 'the Scheme of Amalgamation of Dhanuka LaboratoriesLimited ( Amalgamating Company ) with Orchid Pharma Limited ( Company / Amalgamated Company ) and their respective shareholders and creditors( the Scheme ) under Regulation 30 of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015, as amended'.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma has informed exchanges that the NCLT Chennai Bench has revised the date and venue of the meetings of equity shareholders and unsecured creditors for the proposed amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited. The meeting date has been changed to June 26, 2025, and will now be held through video conferencing from Orchid Pharma's registered office in Alathur, Chengalpattu, Tamil Nadu. This follows the NCLT's earlier order on April 29, 2025, directing that these meetings be convened. The revision was made via NCLT order dated May 9, 2025, which was uploaded on May 13, 2025. The amalgamation scheme is being pursued under SEBI LODR Regulations 2015.
This is a procedural update in the ongoing NCLT process for the amalgamation. Shareholders and creditors of Orchid Pharma will get to vote on the scheme on the revised date of June 26, 2025. Approval at these meetings is a necessary step before the merger can be completed, and the outcome will determine whether Dhanuka Laboratories is absorbed into Orchid Pharma.